184 related articles for article (PubMed ID: 3307402)
1. Conversion from low-dose insulin therapy to glipizide in patients with non-insulin-dependent diabetes mellitus.
Rosenstock J; Meisel A; Raskin P
Am J Med; 1987 Sep; 83(3A):10-5. PubMed ID: 3307402
[TBL] [Abstract][Full Text] [Related]
2. Effects of short-term insulin therapy upon therapeutic response to glipizide.
Schwartz SL; Fischer JS; Kipnes MS; Boyle M
Am J Med; 1987 Sep; 83(3A):22-30. PubMed ID: 3307403
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group.
Simonson DC; Kourides IA; Feinglos M; Shamoon H; Fischette CT
Diabetes Care; 1997 Apr; 20(4):597-606. PubMed ID: 9096986
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of first-generation sulfonylureas and glipizide in non-insulin-dependent diabetes mellitus.
Beisswenger PJ; Dias N; Beckman F
Am J Med; 1987 Sep; 83(3A):16-21. PubMed ID: 3631118
[TBL] [Abstract][Full Text] [Related]
5. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM).
Abraira C; Henderson WG; Colwell JA; Nuttall FQ; Comstock JP; Emanuele NV; Levin SR; Sawin CT; Silbert CK
Diabetes Care; 1998 Apr; 21(4):574-9. PubMed ID: 9571345
[TBL] [Abstract][Full Text] [Related]
6. The effect on metabolic control of second-generation sulfonylurea drugs in patients with NIDDM after secondary failure to first-generation agents.
Sami T; Kabadi UM; Moshiri S
J Fam Pract; 1996 Oct; 43(4):370-4. PubMed ID: 8874372
[TBL] [Abstract][Full Text] [Related]
7. Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea.
Goldstein BJ; Pans M; Rubin CJ
Clin Ther; 2003 Mar; 25(3):890-903. PubMed ID: 12852706
[TBL] [Abstract][Full Text] [Related]
8. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes.
Abraira C; Colwell JA; Nuttall FQ; Sawin CT; Nagel NJ; Comstock JP; Emanuele NV; Levin SR; Henderson W; Lee HS
Diabetes Care; 1995 Aug; 18(8):1113-23. PubMed ID: 7587846
[TBL] [Abstract][Full Text] [Related]
9. The feasibility of intensive insulin management in non-insulin-dependent diabetes mellitus. Implications of the Veterans Affairs Cooperative Study on Glycemic Control and Complications in NIDDM.
Colwell JA
Ann Intern Med; 1996 Jan; 124(1 Pt 2):131-5. PubMed ID: 8554205
[TBL] [Abstract][Full Text] [Related]
10. Bedtime insulin/daytime glipizide. Effective therapy for sulfonylurea failures in NIDDM.
Shank ML; Del Prato S; DeFronzo RA
Diabetes; 1995 Feb; 44(2):165-72. PubMed ID: 7859936
[TBL] [Abstract][Full Text] [Related]
11. Diabetes control in the elderly: a randomized, comparative study of glyburide versus glipizide in non-insulin-dependent diabetes mellitus.
Rosenstock J; Corrao PJ; Goldberg RB; Kilo C
Clin Ther; 1993; 15(6):1031-40. PubMed ID: 8111800
[TBL] [Abstract][Full Text] [Related]
12. [Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin].
Nauck M; del Prato S; Meier JJ; Durán-García S; Rohwedder K; Elze M; Parikh SJ
Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S6-15. PubMed ID: 23529570
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
DeFronzo RA; Goodman AM
N Engl J Med; 1995 Aug; 333(9):541-9. PubMed ID: 7623902
[TBL] [Abstract][Full Text] [Related]
14. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.
Chow CC; Tsang LW; Sorensen JP; Cockram CS
Diabetes Care; 1995 Mar; 18(3):307-14. PubMed ID: 7555472
[TBL] [Abstract][Full Text] [Related]
15. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus.
Meneghini LF; Traylor L; Schwartz SL
Endocr Pract; 2010; 16(4):588-99. PubMed ID: 20350924
[TBL] [Abstract][Full Text] [Related]
16. Comparison of pharmacokinetics, metabolic effects and mechanisms of action of glyburide and glipizide during long-term treatment.
Groop L; Groop PH; Stenman S; Saloranta C; Tötterman KJ; Fyhrquist F; Melander A
Diabetes Care; 1987; 10(6):671-8. PubMed ID: 3123184
[TBL] [Abstract][Full Text] [Related]
17. A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus.
Burge MR; Schmitz-Fiorentino K; Fischette C; Qualls CR; Schade DS
JAMA; 1998 Jan; 279(2):137-43. PubMed ID: 9440664
[TBL] [Abstract][Full Text] [Related]
18. Glibenclamide improves the response to insulin treatment in non-insulin-dependent diabetics with second failure to sulfonylurea therapy.
Lins PE; Lundblad S; Persson-Trotzig E; Adamson U
Acta Med Scand; 1988; 223(2):171-9. PubMed ID: 3126626
[TBL] [Abstract][Full Text] [Related]
19. The combined use of insulin and sulfonylurea therapy in patients with non-insulin dependent diabetes mellitus.
Reaven GM; Fraze E; Chen NY; Hollenbeck C; Chen YD
Horm Metab Res; 1989 Mar; 21(3):132-6. PubMed ID: 2663691
[TBL] [Abstract][Full Text] [Related]
20. Combination of insulin with glipizide increases peripheral glucose disposal in secondary failure type 2 diabetic patients.
Simpson HC; Sturley R; Stirling CA; Reckless JP
Diabet Med; 1990 Feb; 7(2):143-7. PubMed ID: 2137755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
